PDCD1 and cancer: Though pediatric experience with PD-1 inhibitors is limited in myeloid malignancies, nivolumab was shown to be well tolerated in 85 children and young adults with a variety of cancers in a Children’s Oncology Group (COG) trial (ADVL1412) [15].